CINECA IRIS Institutional Research Information System

RIZZONE, Mario Giorgio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.498
EU - Europa 3.085
AS - Asia 1.469
SA - Sud America 104
OC - Oceania 71
AF - Africa 28
Continente sconosciuto - Info sul continente non disponibili 5
Totale 9.260
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.372
CN - Cina 766
IT - Italia 690
SE - Svezia 354
DE - Germania 311
IE - Irlanda 308
FR - Francia 250
GB - Regno Unito 209
FI - Finlandia 166
JP - Giappone 151
UA - Ucraina 148
SG - Singapore 141
ES - Italia 114
KR - Corea 108
PL - Polonia 108
CA - Canada 105
NL - Olanda 91
AT - Austria 87
IN - India 72
VN - Vietnam 69
AU - Australia 66
BR - Brasile 64
BE - Belgio 54
TR - Turchia 44
TW - Taiwan 39
CH - Svizzera 35
RU - Federazione Russa 26
HK - Hong Kong 21
PT - Portogallo 21
MX - Messico 19
AR - Argentina 18
CL - Cile 18
GR - Grecia 18
BG - Bulgaria 15
DK - Danimarca 14
RO - Romania 12
CZ - Repubblica Ceca 10
SN - Senegal 10
UZ - Uzbekistan 10
IL - Israele 9
IR - Iran 7
SI - Slovenia 7
MY - Malesia 6
EG - Egitto 5
EU - Europa 5
IS - Islanda 5
NO - Norvegia 5
NZ - Nuova Zelanda 5
PH - Filippine 5
TH - Thailandia 5
BY - Bielorussia 4
HU - Ungheria 4
RS - Serbia 4
AE - Emirati Arabi Uniti 3
CY - Cipro 3
HR - Croazia 3
MU - Mauritius 3
SK - Slovacchia (Repubblica Slovacca) 3
ZA - Sudafrica 3
BN - Brunei Darussalam 2
CI - Costa d'Avorio 2
EC - Ecuador 2
EE - Estonia 2
ID - Indonesia 2
KZ - Kazakistan 2
LU - Lussemburgo 2
MA - Marocco 2
MD - Moldavia 2
MT - Malta 2
PE - Perù 2
SA - Arabia Saudita 2
TN - Tunisia 2
BA - Bosnia-Erzegovina 1
GH - Ghana 1
GL - Groenlandia 1
MN - Mongolia 1
PK - Pakistan 1
SV - El Salvador 1
Totale 9.260
Salva come PNG Salva come JPEG
Città #
Chandler 587
Beijing 422
Dublin 302
Fairfield 236
Ashburn 212
Torino 200
Houston 184
Redwood City 161
Wilmington 151
Ann Arbor 144
Woodbridge 124
Villeurbanne 121
Nyköping 120
Medford 112
Seattle 111
Princeton 109
Jacksonville 104
Dearborn 101
Cambridge 97
Singapore 82
Warsaw 80
Vienna 79
Pisa 66
Milan 59
Dong Ket 51
Boston 48
Shanghai 43
Madrid 38
Turin 38
Boardman 35
Helsinki 31
Guangzhou 30
New York 28
Hangzhou 27
Taipei 27
Tokyo 25
Seoul 20
Chengdu 19
Fremont 19
Rome 19
London 18
Ottawa 18
Toronto 18
Santiago 17
Brussels 16
Norwalk 16
São Paulo 16
Duncan 15
Nanjing 15
San Diego 15
Verona 15
Edinburgh 14
Düsseldorf 13
Hebei 13
Lachine 13
Amsterdam 12
Jinan 12
Changsha 11
Chicago 11
Chongqing 11
Huntington Station 11
Saint Paul 11
Wuhan 11
Barcelona 10
Groslay 10
Hamburg 10
Hartlepool 10
Hefei 10
Hong Kong 10
Istanbul 10
Melbourne 10
Paris 10
Buenos Aires 9
Cincinnati 9
Gent 9
Mumbai 9
Trento 9
Berlin 8
Fuzhou 8
Los Angeles 8
Minneapolis 8
Napoli 8
Oxford 8
Phoenix 8
Polska 8
Pune 8
Renton 8
Sydney 8
Valencia 8
Zhengzhou 8
Zurich 8
Baton Rouge 7
Essen 7
Mountain View 7
Shenyang 7
Silver Spring 7
Würzburg 7
Ankara 6
Delhi 6
Falls Church 6
Totale 5.091
Salva come PNG Salva come JPEG
Nome #
Parkinson's disease progression at 30 years: a study of subthalamic deep brain-stimulated patients. 713
Impulse control behaviors and subthalamic deep brain stimulation in Parkinson disease 650
Long-term outcome of subthalamic nucleus DBS in Parkinson's disease: from the advanced phase towards the late stage of the disease? 627
Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7-year experience 427
Transient effects of 80 Hz stimulation on gait in STN DBS treated PD patients: a 15 months follow-up study. 327
Subthalamic deep brain stimulation: clinical and neuropsychological outcomes in mild cognitive impaired parkinsonian patients. 318
Medical therapy and subthalamic deep brain stimulation in advanced Parkinson's disease: a different long-term outcome? 259
80 Hz versus 130 Hz subthalamic nucleus deep brain stimulation: effects on involuntary movements. 256
Prospective assessment of peripheral neuropathy in Duodopa-treated parkinsonian patients 253
Subthalamic nucleus deep brain stimulation outcome in young onset Parkinson's disease: a role for age at disease onset? 249
Transdermal apomorphine permeation from microemulsions: a new treatment in Parkinson's disease 230
Does intraoperative microrecording really increase the risk of hemorrhagic complications in deep brain stimulation? 208
Sporadic Fatal Insomnia in Europe: Phenotypic Features and Diagnostic Challenges 172
Nocturnal anomalous movement reduction and sleep microstructure analysis in parkinsonian patients during 1-night transdermal apomorphine treatment. 144
Analisi dei costi della stimolazione cerebrale profonda (DBS) nella malattia di Parkinson: uno studio osservazionale su pazienti italiani. 137
Beyond 35 years of Parkinson’s disease: a comprehensive clinical and instrumental assessment 133
The dominant-subthalamic nucleus phenomenon in bilateral deep brain stimulation for Parkinson's disease: Evidence from a gait analysis study 104
Neurological comorbidity and severity of COVID-19 101
Deep brain stimulation of subthalamic nucleus: behavioral modifications and familiar relations 91
ARGUMENTS IN FAVOUR OF AN EARLIER APPLICATION OF STN-DBS IN THE COURSE OF PARKINSON DISEASE. 88
Role of the cingulate cortex in dyskinesias-reduced-self-awareness: An fMRI study on Parkinson's disease patients 88
Unilateral and bilateral subthalamic nucleus stimulation in Parkinson's disease: effects on EMG signals of lower limb muscles during walking 87
Deep brain stimulation in Parkinson's disease: comparison of pre- and post-operative neuropsychological evaluation 82
Deep brain stimulation of the subthalamic nucleus in PD: an analysis of the exclusion causes 80
3 years comparison between duodopa and Deep Brain Stimulation 79
Role of NOX2 enzyme activity in neuroinflammation: preliminary results in Amyotrophic Lateral Sclerosis and Parkinson’s disease 79
Temporal changes in movement time during the switch of the stimulators in Parkinson's disease patients treated by subthalamic nucleus stimulation. 77
Role of NOX2 enzyme activity in neuroinflammation: preliminary results in Amyotrophic Lateral Sclerosis and Parkinson’s disease 76
Expectation modulates the response to subthalamic nucleus stimulation in Parkinsonian patients. 75
Deep brain stimulation of the subthalamic nucleus: anatomical, neurophysiological and outcome correlations with the effects of stimulation 73
Effect of L-dopa and subthalamic nucleus stimulation on arm and leg swing during gait in Parkinson's Disease. 72
Transdermal rotigotine in dihydropteridine reductase deficiency 72
Apomorphine SC treatment in parkinsonian patients with long-term L-dopa syndrome during L-dopa drug holiday. 70
Beyond Nine Years of Continuous Subthalamic Nucleus Deep Brain Stimulation in Parkinson’s Disease 70
Daytime sleepiness improvement following bilateral chronic electrical stimulation of the subthalamic nucleus in Parkinson's disease. 70
Earlier versus later subthalamic deep brain stimulation in Parkinson's disease 69
The dominant subthalamic nucleus: A gait analysis study 68
Parkinsonian traits in amyotrophic lateral sclerosis (ALS): a prospective population-based study 66
Continuous intraduodenal L-dopa/carbidopa gel infusion improves nocturnal sleep in advanced Parkinson’s disease 65
Controlled-release transdermal apomorphine treatment for motor fluctuations in Parkinson's disease. 64
Deep brain stimulation of the subthalamic nucleus: Clinical effectiveness and safety 64
Deep brain stimulation fine-tuning in Parkinson's disease: Short pulse width effect on speech 63
Long-term effect of levodopa-carbidopa intestinal gel on axial signs in Parkinson’s disease 62
Effects of subthalamic nucleus stimulation and L-dopa in trunk kinematics of patients with Parkinson's disease. 61
Anxiety, depression, and worries in advanced Parkinson disease during COVID-19 pandemic 61
Clinical efficacy of different stimulation frequencies on dyskinesias and dystonias in subthalamic nucleus deep brain stimulation patients with parkinson's disease 60
Is lowering stimulation frequency a feasible option for subthalamic deep brain stimulation in Parkinson's disease patients with dysarthria? 60
Genetic background and outcome of Deep Brain Stimulation in Parkinson's disease 59
Should We Consider Deep Brain Stimulation Discontinuation in Late-Stage Parkinson’s Disease? 59
Deep brain stimulation of the subthalamic nucleus in Parkinson's disease: long-term follow-up. 58
Effects of 80 Hz stimulation on gait in STN-DBS treated PD patients 58
Endovascular Treatment for Acute Ischemic Stroke 58
Deep brain stimulation of the subthalamic nucleus in Parkinson's disease: effects of variation in stimulation parameters. 57
COVID-19 and Parkinson's Disease: What We Know So Far? 57
La stimolazione elettrica ad alta frequenza del nucleo subtalamico nel trattamento chirurgico della malattia di Parkinson. 56
RELAZIONE TRA TARGETING ANATOMICO E NEUROFISIOLOGICO DEL NUCLEO SUBTALAMICO NELLA CHIRURGIA DELLA MALATTIA DI PARKINSON. 55
Motor and non-motor outcomes of subthalamic deep brain stimulation in a case of juvenile PARK-PINK1 54
Association between sleep disorders and cognitive dysfunctions in non-demented patients with advanced Parkinson’s disease 54
Deep brain stimulation of the subthalamic nucleus: selection of patients and clinical results 53
High-frequency electrical stimulation of the subthalamic nucleus in Parkinson's disease: kinetic and kinematic gait analysis 52
Quantitative analysis of gait in Parkinson's disease: a pilot study on the effects of bilateral sub-thalamic stimulation. 52
Levodopa/Carbidopa Intestinal Gel Long-Term Outcome in Parkinson's Disease: Focus on Dyskinesia 52
A new index to assess turning quality and postural stability in patients with Parkinson's disease 50
Peripheral neuropathy in Parkinson’s disease patients treated with duodenal levodopa/carbidopa infusion: A clinical and electrophysiological follow-up study 49
Nocturnal problems and sleep benefit in Parkinson’s disease. 48
Home monitoring of motor fluctuations in Parkinson’s disease patients 48
Tuning Deep Brain Stimulation related depression by frequency modulation: a case report 48
Influence of basal ganglia on upper limb locomotor synergies. Evidence from deep brain stimulation and L-dopa treatment in Parkinson's disease 47
COVID-19 in Parkinson's disease: Report on prevalence and outcome 47
Low frequency subthalamic stimulation and event-related potentials in Parkinson disease 47
Intra-arterial or intravenous thrombolysis for acute ischemic stroke? The SYNTHESIS pilot trial. 46
A man with hyponatremia, confusion, and involuntary limb movements 46
Onset of Covid-19 with impaired consciousness and ataxia: a case report 45
Efficacy of safinamide as add-on therapy after subthalamic nucleus deep brain stimulation in Parkinson disease 45
Sleep improvement with levodopa/carbidopa intestinal gel infusion in Parkinson disease 43
Deep brain stimulation outcomes in the malignant end of Parkinson's disease spectrum 43
Parkinson's clinical features after 30 years of disease: A study from patients treated by subthalamic nucleus stimulation 42
Malattia di Parkinson 41
Neurological comorbidities and COVID-19-related case fatality: A cohort study 39
Focal seizures with impaired awareness as long-term neurological complication of COVID-19: a case report 39
STIMOLAZIONE CEREBRALE PROFONDA DEL NUCLEO SUBTALAMICO : FOLLOW-UP NEUROPSICOLOGICO. 38
Efficacy of subthalamic nucleus stimulation for tremor dystonia: A case report 38
Effects of bilateral subthalamic stimulation on gait kinematics and kinetics in Parkinson's disease 37
Impact of subthalamic nucleus stimulation on the initiation of gait in Parkinson's disease 37
I movimenti involontari: tremori e distonie 37
Long-term duodenal levodopa infusion in Parkinson's disease: a 3-year motor and cognitive follow-up study 36
Management dei principali effetti collaterali della DBS con esempi di casi DBS problemativi 35
Subthalamic deep brain stimulation and trunk posture in Parkinson's disease 35
Prospective assessment of peripheral neuropathy in duodopa treated patients 34
Levodopa-Induced Neuropathy: A Systematic Review 33
Early reversible leukoencephalopathy and unilateral sixth cranial nerve palsy in mild COVID-19 infection 31
Social Cognition deficits in Amyotrophic Lateral Sclerosis: a pilot cross-sectional population-based study 29
SYNTHESIS expansion: design of a nonprofit, pragmatic, randomized, controlled trial on the best fast-track endovascular treatment vs. standard intravenous alteplase for acute ischemic stroke 25
Burden of caregiving for cardiovascular dysautonomia in Parkinson's disease 20
SARS-CoV-2 vaccination, Parkinson's disease, and other movement disorders: case series and short literature review 18
Effects of dopaminergic therapy on sleep quality in fluctuating Parkinson’s disease patients 10
15-Year Subthalamic Deep Brain Stimulation outcome in a Parkinson’s disease patient with Parkin gene mutation: a case report 9
Shared and Unique Disease Pathways in Amyotrophic Lateral Sclerosis and Parkinson's Disease Unveiled in Peripheral Blood Mononuclear Cells 8
Axial symptoms as main predictors of short-term subthalamic stimulation outcome in Parkinson's disease 3
Levodopa-carbidopa intestinal gel infusion (LCIG) in Parkinson disease with genetic mutations 3
Totale 9.563
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.393
article - articoli 0
book - libri 0
conference - conferenze 2.806
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.199
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.202 0 64 85 146 124 145 157 117 131 94 84 55
2020/20211.135 108 141 96 58 82 98 68 75 112 93 75 129
2021/20221.207 66 40 54 99 69 45 51 60 41 109 290 283
2022/20231.782 203 165 60 171 147 412 112 119 162 62 109 60
2023/2024874 92 131 40 57 63 94 33 70 17 81 79 117
2024/202569 53 16 0 0 0 0 0 0 0 0 0 0
Totale 9.569